Quick-Med Technologies, inc. Signs Agreement with Morgan Keegan & Company, Inc. to Serve as Exclusive Financial Advisor

Gainesville, FL (PRWEB) July 24, 2004 -- Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) (Quick-Med Technologies" or the Company"), is pleased to announce that the Company has signed an exclusive engagement agreement with Morgan Keegan & Company, Inc. (Morgan Keegan"), a full-service brokerage and investment banking firm with 145 offices in 15 states and Canada. The agreement provides that Morgan Keegan will serve as the Companys exclusive financial advisor and assist the Company with financial analysis and financial and strategic alternatives. The agreement further provides that Morgan Keegan will assist the Company on a best efforts basis with the identification and securing of equity and/or debt capital and the location and analysis of potential strategic transactions. The terms of the agreement provide that the Company will pay certain cash placement fees based upon the sale of the Companys securities or the closing of an acquisition or otherwise.

David S. Lerner, Quick-Med Technologies President stated We are pleased to have reached this agreement and we look forward to working with Morgan Keegan as our exclusive financial advisor."

About Morgan Keegan & Company, Inc.
Morgan Keegan is a subsidiary of Regions Financial Corporation, a full-service provider of banking, securities brokerage, mortgage, and insurance products and services. Regions Financial Corporation is among the nation's top bank holding companies with assets of more than $80 billion. Regions is a major financial institution in 15 states across the South, Midwest, and Texas with 1,400 branches and more than 140 brokerage offices and trades on the New York Stock Exchange under ticker symbol RF.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused on developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Companys two core products under development are: (1) MultiStat, a family of advanced compounds shown to be effective in broad-based skin therapy applications; and (2) NIMBUS, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer preservatives. Quick-Med Technologies is listed under the symbol QMDT" on the OTC Bulletin Board.

Certain statements in this press release constitute forward-looking statements". Such forward-looking statements involve known and unknown risks, certainties and other factors, which may cause the actual results, performance of achievements of Quick-Med Technologies, Inc. (the Company") to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There is no assurance that the Company will complete any transactions, whether assisted by Morgan Keegan & Company, Inc. or otherwise. The signing of an agreement with Morgan Keegan & Company should not be construed by any means as an indication of the Companys future financial performance or the future value of its common stock. Furthermore, the Companys future operating results are dependent upon many factors, including whether the Company will ever successfully launch its potential technologies and/or products and the risk factors contained in its periodic and other filings. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.

# # #